Daxor Targets Nephrology Market with Blood Volume Analysis Platform at ASN Kidney Week 2026

  • Daxor will exhibit its FDA-cleared Blood Volume Analysis (BVA) platform at ASN Kidney Week 2026 in Denver, October 21–25, 2026.
  • BVA technology aims to address fluid management challenges in complex kidney care, including cardiorenal syndrome and dialysis volume management.
  • Daxor will engage with international nephrology leaders to advance precision medicine for renal disease patients.
  • The company will provide live platform overviews, discuss clinical integration, and review reimbursement pathways at Booth #390.

Daxor's participation in ASN Kidney Week 2026 underscores the growing importance of precise fluid management in nephrology. The event provides a critical platform for Daxor to showcase its BVA technology to a global audience of kidney care professionals, potentially expanding its market reach. The focus on data-driven precision medicine aligns with broader industry trends toward personalized treatment approaches in renal disease management.

Market Expansion
Whether Daxor can leverage ASN Kidney Week 2026 to accelerate adoption of BVA technology among nephrology professionals.
Clinical Integration
The pace at which Daxor can integrate its BVA platform into standard nephrology care protocols.
Reimbursement Pathways
How Daxor's discussions on reimbursement pathways will impact the commercial viability of its BVA technology.